On May 2, 2025, Aditxt, Inc. hosted a weekly update to discuss recent developments regarding their lead therapeutic candidate, ADI-100, which involved the company's CEO and other key executives. This information is part of their ongoing communication with investors and is not formally filed with the SEC.